转录因子NR4A1缺陷增强细菌清除并预防大肠埃希菌肺炎肺损伤
本研究在小鼠大肠埃希菌肺炎模型中探讨NR4A1的作用。体外实验显示NR4A1在肺泡巨噬细胞受大肠埃希菌刺激后15分钟快速诱导,NR4A1缺陷或DIM-C-pPhCO2Me处理增强吞噬功能。体内实验中NR4A1缺陷小鼠48小时生存率显著高于野生型(82.4% vs 33.3%,P<0.01),与DIM-C-pPhCO2Me预处理相当,生存优势伴随细菌负荷和炎症减轻及肺损伤缓解。作者结论为NR4A1损害肺泡巨噬细胞吞噬能力、破坏宿主防御,加重小鼠大肠埃希菌肺炎结局。
要点
- NR4A1缺陷小鼠大肠埃希菌肺炎48小时生存率82.4%,野生型33.3%(P<0.01)。
- NR4A1缺陷或DIM-C-pPhCO2Me处理增强肺泡巨噬细胞对大肠埃希菌的吞噬功能(P<0.001)。
- NR4A1缺陷小鼠生存优势与细菌负荷减少、炎症减轻和肺损伤缓解相关。
- NR4A1在肺泡巨噬细胞受大肠埃希菌刺激后15分钟快速诱导。
- DIM-C-pPhCO2Me预处理小鼠生存获益与NR4A1缺陷相当。
适用人群与场景
- 野生型(WT)与NR4A1敲除(Nr4a1)小鼠,接受大肠埃希菌或假手术肺炎模型。
处置流程与药物剂量
- NR4A1拮抗剂DIM-C-pPhCO2Me用于小鼠体内及体外实验以确认NR4A1的作用。
研究设计与关键结果
- 研究类型为动物实验(小鼠),体外分离野生型和Nr4a1小鼠肺泡巨噬细胞,检测NR4A1表达及对大肠埃希菌的吞噬能力。
- 体外大肠埃希菌刺激后30分钟,NR4A1缺陷组肺泡巨噬细胞吞噬功能为62.3±0.9%,未处理野生型为47.72±0.74%(P<0.001)。
- 体外大肠埃希菌刺激后30分钟,DIM-C-pPhCO2Me处理组肺泡巨噬细胞吞噬功能为30.08±0.79%,未处理野生型为11.79±1.21%(P<0.001)。
- 体内实验中NR4A1缺陷小鼠48小时生存率为82.4%,野生型为33.3%(P<0.01),与DIM-C-pPhCO2Me预处理结果相当。
- NR4A1缺陷小鼠生存优势与细菌负荷减少、炎症减轻及肺损伤缓解相关。
- NR4A1在肺泡巨噬细胞受大肠埃希菌刺激后15分钟快速诱导。
证据类型、等级与局限
- 证据类型:动物实验(小鼠在体与体外实验)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论为NR4A1损害肺泡巨噬细胞吞噬能力、破坏宿主防御、加重小鼠大肠埃希菌肺炎结局,未据此给出临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Bacterial pneumonia is one of the most common diagnoses and a leading cause of death in the intensive care unit. NR4A1 is an early response gene that has been identified as a vital regulator of immune and inflammatory responses. This study aims to explore the role of NR4A1 in Escherichia coli (E. coli) pneumonia.
METHODS: Alveolar macrophages (AMs) were isolated from wild-type (WT) and NR4A1 knock out (Nr4a1) mice, and the NR4A1 expression and phagocytic capacity against E. coli were measured in vitro. WT and Nr4a1 mice were subjected to E. coli or sham pneumonia. Bacterial load, lung injury severity, inflammatory cell infiltration, and cytokines were assessed at 0, 4, and 18 h after surgery. Survival rates within 48 h were evaluated in WT and Nr4a1 mice. In addition, NR4A1 antagonist (DIM-C-pPhCO2Me) was also used to confirm the role of NR4A1 in vivo and ex vivo.
RESULTS: NR4A1 was rapidly induced in AMs at 15 min after E. coli stimulation. Compared with untreated WT AMs, NR4A1 deficiency and DIM-C-pPhCO2Me treatment showed an enhanced phagocytic function (47.72 ± 0.74% vs. 62.3 ± 0.9%, P < 0.001; 11.79 ± 1.21% vs. 30.08 ± 0.79%, P < 0.001, respectively) at 30 min after the E. coli challenge in vitro. NR4A1 deficiency significantly improved the survival rate (33.3% in WT vs. 82.4% in Nr4a1, P < 0.01), which is comparable with DIM-C-pPhCO2Me pretreatment. The survival advantage of Nr4a1 mice was associated with decreased bacterial burden and inflammation and alleviated lung damage.
CONCLUSIONS: These data demonstrate that NR4A1 impairs the phagocytic capacity of AMs and disrupts the host defense against invading bacteria, worsening the outcome of E. coli pneumonia in mice.
参考来源
- Cui P, Wu S, Xu X, et al. Deficiency of the Transcription Factor NR4A1 Enhances Bacterial Clearance and Prevents Lung Injury During Escherichia Coli Pneumonia. Shock. 2019. PMID: 29846361. doi:10.1097/SHK.0000000000001184
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。